The aim of the present study is to conduct a human trial of \[C-11\]OMAR, a new PET imaging agent for the brain cannabinoid type 1 receptors (CB1), to determine its pharmacokinetics and binding characteristics.
This is a pilot, 2-part study to assess the kinetics of radioactivity in medically healthy subjects, subjects with alcohol dependency (AD), and obese subjects following the intravenous administration of the imaging agent \[C-11\]OMAR.
Study Type
OBSERVATIONAL
Enrollment
74
PET radioligand
Yale University School of Medicine
New Haven, Connecticut, United States
No outcome measures for this study, this is an imaging study only
Time frame: Upon study completion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.